Spots Global Cancer Trial Database for abatacept
Every month we try and update this database with for abatacept cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug. | NCT01295151 | Rheumatoid Arth... | Etanercept Abatacept Rituximab Adalimumab Certolizumab Pe... Infliximab Golimumab | 18 Years - | University of Leeds | |
| Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation | NCT03680092 | GVHD Hematologic Neo... | Cyclophosphamid... abatacept Methotrexate Tacrolimus | 18 Years - | University of California, San Diego | |
| Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients | NCT01351480 | Rheumatoid Arth... | abatacept | 18 Years - | Arthritis & Rheumatic Disease Specialties Research | |
| Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients | NCT01351480 | Rheumatoid Arth... | abatacept | 18 Years - | Arthritis & Rheumatic Disease Specialties Research | |
| Abatacept in Immune Checkpoint Inhibitor Myocarditis | NCT05335928 | Myocarditis Acu... Cancer | Abatacept plus Placebo | 18 Years - | Massachusetts General Hospital | |
| Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1) | NCT01350804 | Rheumatoid Arth... | AIN457 Placebo Abatacept | 18 Years - | Novartis | |
| Abatacept as GVHD Prophylaxis Phase 2 | NCT01743131 | Graft vs Host D... Malignancy | Abatacept placebo | 6 Years - | Boston Children's Hospital | |
| SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug. | NCT01295151 | Rheumatoid Arth... | Etanercept Abatacept Rituximab Adalimumab Certolizumab Pe... Infliximab Golimumab | 18 Years - | University of Leeds | |
| Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT | NCT01012492 | AML ALL Undifferentiate... Biphenotypic Le... Refractory Anem... Refractory Anem... Refractory Cyto... Ref. Cytopenia ... Refractory Anem... Refractory Anem... Myelodysplastic... MDS Associated ... | Abatacept | 12 Years - | Boston Children's Hospital | |
| Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past. | NCT00048581 | Rheumatoid Arth... | Abatacept Placebo Abatacept | 18 Years - | Bristol-Myers Squibb | |
| Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1) | NCT01350804 | Rheumatoid Arth... | AIN457 Placebo Abatacept | 18 Years - | Novartis | |
| Abatacept in Immune Checkpoint Inhibitor Myocarditis | NCT05335928 | Myocarditis Acu... Cancer | Abatacept plus Placebo | 18 Years - | Massachusetts General Hospital | |
| A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register | NCT05413044 | Rheumatoid Arth... Psoriatic Arthr... | 18 Years - | Bristol-Myers Squibb | ||
| Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT | NCT01012492 | AML ALL Undifferentiate... Biphenotypic Le... Refractory Anem... Refractory Anem... Refractory Cyto... Ref. Cytopenia ... Refractory Anem... Refractory Anem... Myelodysplastic... MDS Associated ... | Abatacept | 12 Years - | Boston Children's Hospital | |
| Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - TNFi vs Abatacept | NCT04529902 | Rheumatoid Arth... | Tumor Necrosis ... Abatacept | 18 Years - | Brigham and Women's Hospital | |
| Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past. | NCT00048581 | Rheumatoid Arth... | Abatacept Placebo Abatacept | 18 Years - | Bristol-Myers Squibb | |
| A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database | NCT05421442 | Rheumatoid Arth... Psoriatic Arthr... | 18 Years - | Bristol-Myers Squibb | ||
| Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation | NCT03680092 | GVHD Hematologic Neo... | Cyclophosphamid... abatacept Methotrexate Tacrolimus | 18 Years - | University of California, San Diego | |
| A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register | NCT05413044 | Rheumatoid Arth... Psoriatic Arthr... | 18 Years - | Bristol-Myers Squibb | ||
| Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1) | NCT01350804 | Rheumatoid Arth... | AIN457 Placebo Abatacept | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
